EVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Evaxion A/S
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 5, 2026
$3.33+0.50 (+17.67%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Operating margin
-122.7%
Net margin
-102.4%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +125.1% | – | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | -130.3% | -37.7% | |
| Current ratio | – | 2.22 | 5.85 | |
| Interest coverage | – | -74.3× | -2.3× | |
| Capex to revenue | – | – | 0.1% | |
| Diluted shares | – | 15M | 320M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Evaxion A/S generated $84.96M from operations and spent $1.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$84.96M
Used
$1.69M
Capital expenditure$1.69M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.71M
- Cash generatingOperating cash flow above zero-$6.63M
- Return on assets improvedROA up on the prior year-82.0% → -61.7%
- Earnings backed by cashOperating cash flow above net income-$6.63M vs -$7.71M
- Less leverageLong-term debt to assets fell64.1% → 18.8%
- Better liquidityCurrent ratio rose2.01 → 5.85
- No dilutionShare count did not rise54M → 320M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.26 → 0.60